Kristina Callis Duffin, MD, MS

Journal Article

1. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock A (2012). Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. American journal of human genetics, 90(5), 796-808. (Read full publication)
2. Narayanan S, Callis-Duffin K, Batten J, Agarwal (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. The American journal of the medical sciences, 339(6), 580-1. (Read full publication)
3. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF J (2012). Consensus guidelines for the management of plaque psoriasis. Archives of dermatology, 148(1), 95-102. (Read full publication)
4. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees A (2012). Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Archives of dermatology, 148(4), 487-94. (Read full publication)
5. Nair RP, Ding J, Duffin KC, Helms C, Voorhees JJ, Krueger GG, Bowcock AM, Abeçasis GR, Elder J (2009). Psoriasis bench to bedside: genetics meets immunology. Archives of dermatology, 145(4), 462-4. (Read full publication)
6. Taliercio VL, Snyder AM, Biggs AM, Kean J, Hess R, Duffin KC, Cizik AM, Secrest A (2021). Clinicians' perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. Quality of life research, 31(6), 1719-1725. (Read full publication)
7. Callis Duffin K, Wong B, Horn EJ, Krueger G (2009). Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. Journal of the American Academy of Dermatology, 60(4), 604-8. (Read full publication)
8. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand J (2013). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology, 68(1), 64-72. (Read full publication)
9. Grande-Sarpa H, Callis Duffin KP, Florell S (2008). Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 59(1), 154-7. (Read full publication)
10. Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand J (2019). Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. Journal of the American Academy of Dermatology, 81(4), 923-930. (Read full publication)
11. Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola J (2020). Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Journal of the American Academy of Dermatology, 82(1), 54-61. (Read full publication)
12. Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, Duffin KC, Reeder M, Merola JF, Swerlick R (2019). Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. Journal of the American Academy of Dermatology, 88(1), 86-93. (Read full publication)
13. Taliercio V, Langner AU, Secrest AM, Duffin K (2020). Research Letter Measuring quality in psoriasis: early experiences with the MIPS 410 quality measure-cross sectional study. Journal of the American Academy of Dermatology, (Read full publication)
14. Taliercio V, Langner AU, Secrest AM, Duffin K (2021). Assessing psoriasis severity: psychometric validation of overall physician global assessment (OPGA). Journal of the American Academy of Dermatology, 86(3), 637-638. (Read full publication)
15. Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger G (2009). Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. The Journal of investigative dermatology, 129(12), 2777-83. (Read full publication)
16. Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta N (2020). A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). The Journal of investigative dermatology, 140(9), 1784-1793.e2. (Read full publication)
17. Walsh JA, Callis Duffin K, Krueger GG, Clegg D (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. The Journal of rheumatology, 40(3), 287-93. (Read full publication)
18. Callis Duffin K, Mease P (2011). Psoriasis and Psoriatic Arthritis Video Project 2010: a report from the GRAPPA annual meeting. The Journal of rheumatology, 38(3), 562-3. (Read full publication)
19. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng B (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. The Journal of rheumatology, 48(10), 1559-1565. (Read full publication)
20. Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett (2019). The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. The Journal of rheumatology. Supplement, 95, 33-37. (Read full publication)
21. Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald (2019). Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. The Journal of rheumatology. Supplement, 95, 11-19. (Read full publication)
22. Callis Duffin K, Gladman DD, Gottlieb AB, Goel (2019). Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Journal of rheumatology. Supplement, 95, 1-3. (Read full publication)
23. Duffin KC, Gottlieb AB, O'Sullivan D, Gladman DD, McFarland L (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Journal of rheumatology. Supplement, 97, 1-3. (Read full publication)
24. Duffin KC, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola JF, Chau J, Kishimoto M, Furer V, Helliwell P (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. The Journal of rheumatology. Supplement, 97, 34-38. (Read full publication)
25. Mease PJ, Calabrese LH, Duffin KC, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola J (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. The Journal of rheumatology. Supplement, 97, 24-29. (Read full publication)
26. Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo (2019). A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC dermatology, 19(1), 8. (Read full publication)
27. Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AV (2019). Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American journal of clinical dermatology, 20(5), 699-709. (Read full publication)
28. Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong A (2020). Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. American journal of clinical dermatology, 21(3), 323-338. (Read full publication)
29. Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar D (2009). Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS genetics, 5(8), e1000606. (Read full publication)
30. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin K (2013). Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA dermatology, 149(5), 577-82. (Read full publication)
31. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest A (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA dermatology, 156(10), 1074-1078. (Read full publication)
32. Wong B, Machan M, Krueger GG, Callis Duffin (2011). Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients With and Without Psoriasis. Psoriasis forum, 17(3), 209-215.
33. Blauvelt A,Papp K,Gottlieb A,Jarell A,Reich K,Maari C,Gordon KB,Ferris LK,Langley RG,Tada Y,Lima RG,Elmaraghy H,Gallo G,Renda L,Park SY,Burge R,Bagel J,Vender R,Lomaga MA,Delorme I,Hong CH,Langley RL,Albrecht L,Guenther L,Maari C,Papp K,Singh Ohson KK,Barber K,Lynde C,Gupta A,Rosoph L,Gauthier JS,Gooderham M,Wasel N,Raman M,Wiseman M,Greenstein D,Jarell A,Moon C,Clark L,Jazayeri SS,Bukhalo M,Moore A,Hamilton TK,Gewirtzman A,Hazan L,Crowley J,Teller C,Zirwas M,Smith SR,Christine Lee M,Tyring S,Lee P,Dhawan S,Leonardi C,Jesus APD,McFalda W,Frankel E,Yamauchi P,Fretzin S,Serrao R,Schlesinger T,Gottlieb S,Jenkin P,Gharib R,Davis S,Nami N,Draelos ZD,Godwin L,Owen C,Landis M,Abramovits W,Sanchez-Rivera S,Van Voorhees A,Fivenson D,Kerdel F,Forman SB,Weinberg J,Gonzalez-Chavez J,Boyce B,Stein-Gold L,Hudson C,Brown C,Coggi J,Feser C,Forconi R,Johnson S,McCune M,Green L,Madkan V,Shipp DM,Gordon KB,Waibel J,Soto-Raices O,Cather J,Miller S,Scott J,Young D,Kaffenberger J,Yokum (2020). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. The British journal of dermatology, 182(6), 1348-1358. (Read full publication)
34. Duffin KC,Gladman DD,Goel N,Gottlieb A (2020). Prologue: 2019 annual meeting of the group for research and assessment of psoriasis and psoriatic arthritis (grappa). The Journal of rheumatology, 96, 1-3. (Read full publication)
35. Coates LC,Merola JF,Grieb SM,Mease PJ,Duffin K (2020). Methotrexate in psoriasis and psoriatic arthritis. The Journal of rheumatology, 96, 31-35. (Read full publication)
36. Leung YY,Tillett W,Orbai AM,Ogdie A,Eder L,Coates LC,Holland R,Antony A,Goel N,Mease PJ,Strand V,FitzGerald O,De Wit M,Lindsay CA,Duffin KC,Gladman D (2020). The grappa-omeract working group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates. The Journal of rheumatology, 96, 46-49. (Read full publication)
37. Waxman R,Stober C,Jadon DR,Orbai AM,Chandran V,Ogdie A,Pennington SR,De Wit M,O'Sullivan D,Mease PJ,Armstrong AW,Callis Duffin K,Helliwell PS,Van Mens LJJ,Ritchlin CT,FitzGerald (2020). Proceedings of the 2019 grappa collaborative research network meeting. The Journal of rheumatology, 96, 25-30. (Read full publication)
38. Callis Duffin K,Mason MA,Gordon K,Harrison RW,Crabtree MM,Guana A,Germino R,Lebwohl (2021). Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology (Basel, Switzerland), 237(1), 46-55. (Read full publication)
39. Kornmehl H,Callis Duffin K,Salame N,Perez-Chada LM,Singh S,Garg A,Gottlieb AB,Latella J,Merola JF,Armstrong A (2021). Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology (Basel, Switzerland), 237(2), 151-157. (Read full publication)
40. Stein Gold L,Papp K,Pariser D,Green L,Bhatia N,Sofen H,Albrecht L,Gooderham M,Chen M,Paris M,Wang Y,Callis Duffin (2022). Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 86(1), 77-85. (Read full publication)
41. Walsh JA,Callis Duffin K,Van Voorhees AS,Chakravarty SD,Fitzgerald T,Teeple A,Rowland K,Uy J,McLean RR,Malley W,Cronin A,Merola J (2022). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas¿ Psoriasis Registry. Dermatology and therapy, 12(1), 97-119. (Read full publication)
42. Noe MH,Wan MT,Mostaghimi A,Gelfand JM,Agnihothri R,Armstrong AW,Bhutani T,Bridges A,Brownstone N,Butt M,Duffin KPC,Carr C,Creadore A,Deniro KL,Desai S,Dominguez AR,Duffy EK,Fairley JA,Femia A,Gudjonsson JE,Kaffenberger JA,Katz KL,Le ST,Martinez E,Maverakis E,Myers B,Naik HB,Nelson CA,Ortega-Loayza AG,Plovanich ME,Rangel LK,Ravi V,Reddy VD,Saleh JZ,Kirby JS,Sandhu JK,Shakshouk H,Shields BE,Sharif-Sidi Z,Smith J,Steahr A,Toussi A,Wanat KA,Wang B,Wei BM,Weinhammer A,Worswick SD,Yang (2022). Evaluation of a Case Series of Patients with Generalized Pustular Psoriasis in the United States. JAMA dermatology, 158(1), 73-78. (Read full publication)
43. Ogdie A,Lindsay CA,Mease PJ,Duffin KC,Rosen CF,Siebert (2022). Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. The Journal of rheumatology, 49(6), 64-67. (Read full publication)
44. Duffin KC,Gladman DD,Goel N,Gottlieb AB,FitzGerald O,McFarland L (2022). Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Journal of rheumatology, 49(6), 1-3. (Read full publication)
45. Armstrong AW,Reddy RM,FitzGerald O,Duffin KC,Helliwell PS,Mease PJ,Kavanaugh A,Merola JF,Tillet W,Wit M (2022). 2021 GRAPPA Meet the Experts Session: A Summary of Presentations. The Journal of rheumatology, 49(6), 32-36. (Read full publication)
46. Takeshita J,Chau J,Duffin KC,Goel (2022). Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. The Journal of rheumatology, 49(6), 48-51. (Read full publication)
47. Coates LC,Soriano ER,Corp N,Bertheussen H,Callis Duffin K,Campanholo CB,Chau J,Eder L,Fernández-Ávila DG,FitzGerald O,Garg A,Gladman DD,Goel N,Helliwell PS,Husni ME,Jadon DR,Katz A,Laheru D,Latella J,Leung YY,Lindsay C,Lubrano E,Mazzuoccolo LD,Mease PJ,O'Sullivan D,Ogdie A,Olsder W,Palominos PE,Schick L,Steinkoenig I,de Wit M,van der Windt DA,Kavanaugh A,Campanholo CB,Fitzgerald O,Gladman D,Helliwell P,Husni ME,Laheru D,Leung YY,Lubrano E,Mazzuoccolo LD,Mease PJ,Ogdie A,Palominos P (2022). Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature reviews. Rheumatology, 18(8), 465-479. (Read full publication)
48. Coates LC,Soriano ER,Corp N,Bertheussen H,Callis Duffin K,Campanholo CB,Chau J,Eder L,Fernández-Ávila DG,FitzGerald O,Garg A,Gladman DD,Goel N,Helliwell PS,Husni ME,Jadon DR,Katz A,Laheru D,Latella J,Leung YY,Lindsay C,Lubrano E,Mazzuoccolo LD,Mease PJ,O'Sullivan D,Ogdie A,Olsder W,Palominos PE,Schick L,Steinkoenig I,de Wit M,van der Windt DA,Kavanaugh A,Campanholo CB,Fitzgerald O,Gladman D,Helliwell P,Husni ME,Laheru D,Leung YY,Mazzuoccolo LD,Mease PJ,Ogdie A,Palominos P (2022). Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (Nature Reviews Rheumatology, (2022), 18, 8, (465-479), 10.1038/s41584-022-00798-0). Nature reviews. Rheumatology, 18(12), 734. (Read full publication)
49. Gold LS,Papp K,Pariser D,Bhatia N,Sofen H,Albrecht L,Gooderham M,Duffin KC,Chen M,Paris M,Cheng S,Picard H,Wang Y,Green (2023). Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. Journal of the American Academy of Dermatology, 88(2), 430-433. (Read full publication)
50. Armstrong AW,Fitzgerald T,McLean RR,Teeple A,Uy JP,Olurinde M,Rowland K,Guo L,Shan Y,Callis Duffin (2023). Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ¿ 2 in the CorEvitas Psoriasis Registry. Dermatology and therapy, 13(2), 487-504. (Read full publication)
51. Armstrong AW,Fitzgerald T,McLean RR,Teeple A,Uy JP,Olurinde M,Rowland K,Guo L,Shan Y,Callis Duffin (2023). Real-World Effectiveness of 9¿12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Dermatology and therapy, 13(2), 629-640. (Read full publication)
52. Hopkins ZH, Kuceki G, Taliercio VL, Snyder AM, Stoddard GJ, Duffin KC, Hess R, Secrest A (2022). Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. Archives of dermatological research, (Read full publication)
53. Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Alexander AN, Tang M, Thoma C, Duffin K (2023). The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. The British journal of dermatology, (Read full publication)
54. Strober B, Ferris L, Duffin KC, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Armstrong (2023). Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis using the CorEvitas Psoriasis Registry. Journal of the American Academy of Dermatology, (Read full publication)
55. Duffin KC Md M (2015). Screening and Monitoring Before and During Systemic Therapy: Recommendations for Patients With Psoriasis. Seminars in cutaneous medicine and surgery, 34(2 Suppl), S40-2. (Read full publication)
56. Duffin KC Md M (2015). Identifying and Managing Complications and Comorbidities in Patients With Psoriasis. Seminars in cutaneous medicine and surgery, 34(2 Suppl), S30-3. (Read full publication)
57. Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng B (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis care & research, 76(3), 421-425. (Read full publication)
58. Callis Duffin K, Hwang ST, Krueger J (2023). Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis. The Journal of rheumatology, (Read full publication)
59. Ng BCK, Jadon D, Adebajo A, Ayan G, Callis Duffin K, Chandran V, Coates LC, D'Agostino MA, de Vlam K, Deodhar A, Eder L, Garg A, Gladman DD, Goel N, Gottlieb AB, Husni ME, Katz A, Kavanaugh A, Lubrano E, Mease PJ, Merola JF, Nash P, Ogdie A, Pennington SR, Perez-Chada LM, Proft F, Rosen CF, Savage L, Goldenstein-Schainberg C, Siebert S, Soriano ER, Steinkoenig I, Tillett W, Armstrong AW, FitzGerald (2023). Proceedings of the GRAPPA 2022 Executive Retreat. The Journal of rheumatology, (Read full publication)
60. Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin (2023). The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Advances in therapy, 40(5), 2493-2508. (Read full publication)
61. Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola J (2022). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatology and therapy, 12(1), 97-119. (Read full publication)
62. Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola J (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. The Journal of rheumatology, (Read full publication)
63. Callis Duffin K, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola J, Chau J, Kishimoto M, Furer V, Helliwell P (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. The Journal of rheumatology, (Read full publication)
64. Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Callis Duffin K, Gladman D (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. The Journal of rheumatology, (Read full publication)
65. Callis Duffin K, Gottlieb AB, O'Sullivan D, Gladman DD, McFarland L (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Journal of rheumatology, (Read full publication)
66. Strober B, Duffin KC, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel (2024). Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. The Journal of dermatological treatment, 35(1), 2287401. (Read full publication)
67. Garg A, Noe MH, Anadkat MJ, Armstrong A, Bhutani T, Farberg A, Han G, Hawkes JE, Lebwohl M, Rekhtman S, Song EJ, Strunk A, Duffin K (2024). Development of the Generalized Pustular Psoriasis Clinical Assessment Tool. Journal of the American Academy of Dermatology, 90(1), 192-195. (Read full publication)
68. Chat VS, Ellebrecht CT, Kingston P, Bell S, Gondo G, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong A (2024). Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, (Read full publication)
69. Carroll C, Aðalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng B (2024). Measuring Psoriasis Severity at Home. Journal of visualized experiments, (205), (Read full publication)
70. Rhoads JLW, Malatestinic WN, Burge R, Ganz ML, Duffin K (2024). Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data. Journal of psoriasis and psoriatic arthritis, 9(1), 5-15. (Read full publication)
71. Liao W, Armstrong AW, Duffin K (2024). GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis. The Journal of rheumatology, 51(Suppl 2), 89-92. (Read full publication)
72. Carroll C, Adalsteinsson JA, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng B (2024). Erratum: Measuring Psoriasis Severity at Home. Journal of visualized experiments, (213), (Read full publication)
73. Armstrong AW, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, Yousif J, Grant C, Shields A, Chou P, Callis Duffin K, Gottlieb AB, Merola JF, Perez-Chada (2025). Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis. JAMA dermatology, (Read full publication)
74. Gelfand JM, Armstrong AW, Lim HW, Feldman SR, Johnson SM, Claiborne WCC, Kalb RE, Jakus J, Mangold AR, Flowers RH, Bhutani T, Durkin JR, Bagel J, Fretzin S, Sheehan MP, Krell J, Reeder M, Kaffenberger J, Kartono F, Takeshita J, Bridges AM, Fielding E, Nehal US, Schaecher KL, Howard LM, Eakin GS, Báez S, Bishop BE, Fitzsimmons RC Jr, Papadopoulos M, Song WB, Linn KA, Hubbard RA, Shin DB, Callis Duffin (2024). Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA dermatology, 160(12), 1320-1328. (Read full publication)
75. Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin KC, Fakharzadeh S, Feldman SR, Gelfand JM, Gladman DD, Glick B, Green LJ, Han G, Hawkes JE, Hwang ST, Johnsen N, Kalb RE, Kircik L, Langley RG, Lebwohl MG, Lewitt GM, Maverakis E, Prussick R, Reddy SM, Rosen CF, Scher JU, Siegel EL, Wallace EB, Weinberg JM, Yamauchi PS, Yosipovitch G, Liao W, Remission Workgroup of the National Psoriasis Foundatio (2025). Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. JAMA dermatology, (Read full publication)
76. Gkini MA, Chinchay L, Lindsay CA, Franco M, Castro Ayarza JR, Duffin K (2025). Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting. The Journal of rheumatology, 52(Suppl 3), 19-22. (Read full publication)
77. Ney Z, Ringwood D, Takara M, Frost Z, Conley M, Kean J, Secrest A, Duffin KC, Hopkins (2025). Clinical assessment implications from core outcome domain set development exercises in dermatology. Journal of the American Academy of Dermatology, (Read full publication)
78. Blauvelt A, Prussick R, Merola JF, Shahriari M, Cather J, Eakin GS, McCormick Howard L, Lebwohl MG, Armstrong AW, Duffin K (2025). Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board. Journal of the American Academy of Dermatology, (Read full publication)

Review

1. Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong A (2018). Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). Dermatology (Basel, Switzerland), 234(3-4), 112-119. (Read full publication)
2. deShazo RA,Secrest AM,Armstrong AW,Duffin K (2020). Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. Journal of psoriasis and psoriatic arthritis, (Read full publication)
3. Duffin KC, Mazzuoccolo LD, Cura MJ, Esposito M, Fernandez AP, Gisondi P, Giunta A, Hillary T, Piaserico S, Solomon JA, Merola J (2023). Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of rheumatology, 50(1), 131-143. (Read full publication)
4. Choon SE,Van De Kerkhof P,Gudjonsson JE,De La Cruz C,Barker J,Morita A,Romiti R,Affandi AM,Asawanonda P,Burden AD,Gonzalez C,Marrakchi S,Mowla MR,Okubo Y,Oon HH,Terui T,Tsai TF,Callis-Duffin K,Fujita H,Jo SJ,Merola J,Mrowietz U,Puig L,Thaçi D,Velásquez M,Augustin M,El Sayed M,Navarini AA,Pink A,Prinz J,Turki H,Magalhães R,Capon F,Bachelez (2024). International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis from the International Psoriasis Council. JAMA dermatology, 160(7), 758-768. (Read full publication)
5. Duffin KC, Thio HB, Helliwell P (2024). Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update. The Journal of rheumatology, 51(Suppl 2), 77-79. (Read full publication)
6. Ball GD, Hamade H, Gottlieb AB, Kirby B, Duffin K (2024). GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?. The Journal of rheumatology, 51(Suppl 2), 39-42. (Read full publication)
7. Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola J (2025). Psoriasis. Nature reviews. Disease primers, 11(1), 45. (Read full publication)

Conference Proceedings

1. Duffin KC,Mease P (2015). Psoriasis and psoriatic arthritis educational initiatives: An update from the 2014 GRAPPA annual meeting. The Journal of rheumatology, 42(6), 1056-1058. (Read full publication)

Editorial

1. Hopkins ZH, Perez Chada LM, Duffin K (2023). Defining what matters through core outcomes set development: Uniting stakeholder perspectives, empowering patient voices. The British journal of dermatology, (Read full publication)

Letter

1. Romagosa R,Kerdel F,Shah N,Krueger G,Callis (2002). Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease [6]. Journal of the American Academy of Dermatology, 47(6), 970-972. (Read full publication)

Other

1. Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Duffin KC, Gladman D (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. The Journal of rheumatology. Supplement, 97, 60-63. (Read full publication)

News

• Chair of Department of Dermatology Named at University of Utah
• Patrol Your Moles: What They Mean for Your Skin Health
• Kristina Callis Duffin, MD, MS, appointed Interim Dean of the Spencer Fox Eccles School of Medicine at the University of Utah